Therefore, the present study investigated how downregulation in the expression levels of Smad2 and Smad3 affected glioma cell proliferation, and whether GBM cell proliferation was controlled differentially by Smad2 and Smad3. This evidence concerns the gene SMAD2 and central nervous system cancer.